Goldman Sachs’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$356M Sell
386,800
-185,000
-32% -$188M 0.04% 445
2025
Q4
$615M Sell
571,800
-11,300
-2% -$10.8M 0.08% 244
2025
Q3
$445M Buy
583,100
+381,700
+190% +$284M 0.05% 339
2025
Q2
$157M Buy
201,400
+186,200
+1,225% +$145M 0.02% 654
2025
Q1
$12.6M Sell
15,200
-12,600
-45% -$10.5M ﹤0.01% 2474
2024
Q4
$21.5M Sell
27,800
-52,800
-66% -$43.7M ﹤0.01% 2064
2024
Q3
$71.4M Sell
80,600
-29,700
-27% -$26.7M 0.01% 981
2024
Q2
$99.9M Buy
110,300
+38,500
+54% +$30.8M 0.02% 798
2024
Q1
$55.9M Sell
71,800
-98,000
-58% -$69.7M 0.01% 1090
2023
Q4
$99M Sell
169,800
-32,600
-16% -$19M 0.02% 792
2023
Q3
$109M Buy
202,400
+71,600
+55% +$36.9M 0.02% 678
2023
Q2
$61.3M Buy
130,800
+74,800
+134% +$31.4M 0.01% 960
2023
Q1
$19.2M Sell
56,000
-33,200
-37% -$11.2M ﹤0.01% 1849
2022
Q4
$32.6M Sell
89,200
-29,200
-25% -$10.4M 0.01% 1525
2022
Q3
$38.3M Sell
118,400
-28,000
-19% -$8.87M 0.01% 1309
2022
Q2
$47.5M Sell
146,400
-14,500
-9% -$4.35M 0.01% 1157
2022
Q1
$46.1M Sell
160,900
-17,800
-10% -$4.58M 0.01% 1342
2021
Q4
$49.4M Buy
178,700
+128,300
+255% +$32.5M 0.01% 1354
2021
Q3
$11.6M Sell
50,400
-7,000
-12% -$1.73M ﹤0.01% 2577
2021
Q2
$13.2M Sell
57,400
-115,000
-67% -$23.1M ﹤0.01% 2435
2021
Q1
$32.2M Sell
172,400
-108,800
-39% -$21.3M 0.01% 1526
2020
Q4
$47.5M Buy
281,200
+175,400
+166% +$26.2M 0.01% 1164
2020
Q3
$15.7M Sell
105,800
-36,000
-25% -$5.57M ﹤0.01% 1934
2020
Q2
$23.3M Buy
141,800
+111,500
+368% +$17.1M 0.01% 1556
2020
Q1
$4.2M Buy
30,300
+15,600
+106% +$2.14M ﹤0.01% 2775
2019
Q4
$1.93M Sell
14,700
-58,900
-80% -$6.83M ﹤0.01% 3672
2019
Q3
$8.23M Buy
73,600
+11,300
+18% +$1.26M ﹤0.01% 2474
2019
Q2
$6.9M Sell
62,300
-699,100
-92% -$82.3M ﹤0.01% 2625
2019
Q1
$98.8M Buy
761,400
+288,600
+61% +$35.1M 0.03% 672
2018
Q4
$54.7M Buy
472,800
+397,700
+530% +$44.4M 0.02% 1025
2018
Q3
$8.06M Sell
75,100
-123,500
-62% -$12.3M ﹤0.01% 2617
2018
Q2
$16.9M Sell
198,600
-108,900
-35% -$8.94M ﹤0.01% 2018
2018
Q1
$23.8M Buy
307,500
+66,900
+28% +$5.39M 0.01% 1714
2017
Q4
$20.3M Buy
240,600
+12,400
+5% +$1.06M ﹤0.01% 1936
2017
Q3
$19.5M Sell
228,200
-28,000
-11% -$2.3M ﹤0.01% 2007
2017
Q2
$21.1M Buy
256,200
+63,600
+33% +$5.19M 0.01% 1886
2017
Q1
$16.2M Sell
192,600
-447,500
-70% -$35.8M ﹤0.01% 2038
2016
Q4
$47.1M Sell
640,100
-55,200
-8% -$4.11M 0.01% 1314
2016
Q3
$55.8M Buy
695,300
+275,900
+66% +$22.1M 0.02% 1117
2016
Q2
$33M Sell
419,400
-237,300
-36% -$17.9M 0.01% 1407
2016
Q1
$47.3M Buy
656,700
+466,500
+245% +$35.3M 0.02% 1112
2015
Q4
$16M Sell
190,200
-77,400
-29% -$6.42M 0.01% 1913
2015
Q3
$22.4M Buy
267,600
+79,200
+42% +$6.69M 0.01% 1635
2015
Q2
$15.7M Sell
188,400
-168,200
-47% -$12.8M ﹤0.01% 1981
2015
Q1
$25.9M Buy
356,600
+54,100
+18% +$3.85M 0.01% 1567
2014
Q4
$20.9M Buy
302,500
+32,400
+12% +$2.19M 0.01% 1792
2014
Q3
$17.5M Sell
270,100
-29,200
-10% -$1.85M 0.01% 1894
2014
Q2
$18.6M Sell
299,300
-126,600
-30% -$7.55M 0.01% 1848
2014
Q1
$25.1M Sell
425,900
-253,600
-37% -$14.2M 0.01% 1579
2013
Q4
$34.7M Sell
679,500
-43,100
-6% -$2.16M 0.01% 1331
2013
Q3
$36.4M Buy
722,600
+272,900
+61% +$14.3M 0.01% 1186
2013
Q2
$22.1M Buy
+449,700
New +$24.5M 0.01% 1472

Other funds holding LLY

Goldman Sachs's LLY Position: Q1 2026 in Review

Goldman Sachs increased its Eli Lilly (LLY) stake by 6.6% in Q1 2026, buying an estimated $396M and bringing the position to 6,340,865 shares worth $5.83B. The position accounts for 0.67% of the portfolio, ranked #15.

Goldman Sachs first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.39B in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Goldman Sachs held 6,340,865 shares of Eli Lilly worth $5.83B as of Q1 2026.
  • Goldman Sachs bought 390,971 Eli Lilly shares in Q1 2026, an estimated $396M.
  • Eli Lilly made up 0.67% of Goldman Sachs's portfolio in Q1 2026, its #15 holding.
  • Goldman Sachs first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Eli Lilly position peaked at $6.39B in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.